Markets:

Overview

News

Currencies

International

Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

10.70 -0.49 (-4.38%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 06, 2025

Via Benzinga

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease ↗

November 06, 2025

Via Stocktwits

Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock ↗

October 21, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics ↗

March 03, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts ↗

February 10, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts ↗

January 13, 2025

Via Benzinga

Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec' ↗

September 03, 2025

Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the table just to be prudent," he said.

Via Benzinga

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics ↗

August 12, 2025

Via Benzinga

4dMT Revenue Jumps 200 Percent in Q2 ↗

August 11, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 04, 2025

Via Benzinga

Unusual volume stocks in Monday's session ↗

August 04, 2025

Unusual volume stocks are being observed in Monday's session.

Via Chartmill

What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics ↗

December 18, 2024

Via Benzinga

Analyst Expectations For 4D Molecular Therapeutics's Future ↗

November 14, 2024

Via Benzinga

Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts ↗

August 01, 2025

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

August 01, 2025

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

August 01, 2025

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study ↗

August 01, 2025

4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.

Via Benzinga

The Latest Analyst Ratings For 4D Molecular Therapeutics ↗

September 09, 2024

Via Benzinga

These stocks that are showing activity before the opening bell on Friday. ↗

August 01, 2025

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 01, 2025

Via Benzinga

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

August 01, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 31, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

July 31, 2025

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics ↗

July 03, 2025

Via Benzinga

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study ↗

February 10, 2025

4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Via Benzinga

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

December 18, 2024

Via Benzinga

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate ↗

September 19, 2024

4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to...

Via Benzinga

FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024 ↗

August 09, 2024

FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.